RAS Interaction with PI3K: More Than Just Another Effector Pathway
Open accessThe DOI matches its Crossref record; 205 of the 206 references it cites were found in a registry or an index.
Abstract
RAS PROTEINS ARE SMALL GTPASES KNOWN FOR THEIR INVOLVEMENT IN ONCOGENESIS: around 25% of human tumors present mutations in a member of this family. RAS operates in a complex signaling network with multiple activators and effectors, which allows them to regulate many cellular functions such as cell proliferation, differentiation, apoptosis, and senescence. Phosphatidylinositol 3-kinase (PI3K) is one of the main effector pathways of RAS, regulating cell growth, cell cycle entry, cell survival, cytoskeleton reorganization, and metabolism. However, it is the involvement of this pathway in human tumors that has attracted most attention. PI3K has proven to be necessary for RAS-induced transformation in vitro, and more importantly, mice with mutations in the PI3K catalytic subunit p110α that block its ability to interact with RAS are highly resistant to endogenous oncogenic KRAS-induced lung tumorigenesis and HRAS-induced skin carcinogenesis. These animals also have a delayed development of the lymphatic vasculature. Many PI3K inhibitors have been developed that are now in clinical trials. However, it is a complex pathway with many feedback loops, and interactions with other pathways make the results of its inhibition hard to predict. Combined therapy with another RAS-regulated pathway such as RAF/MEK/ERK may be the most effective way to treat cancer, at least in animal models mimicking the human disease. In this review, we will summarize current knowledge about how RAS regulates one of its best-known effectors, PI3K.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Network analysis of the several driver mutation genes, including KMT2D138, PIK3CA139, PTEN140, and IDH1141, that regulate signaling and metabolic pathways in KRAS-driven cancers, connects them to oncogenic RAS (Fig 4c).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Oncogenic KRAS signaling also involves PI3K-AKT-mTOR, via the interaction with the catalytic subunits of PI3K (78–80).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“An additional layer of complexity is the cross-regulation between the two pathways with ERK signaling feeding into several nodes of PI3K/mTOR such as its phosphorylation of TSC236–38.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Li, W., Zhu, T., & Guan, K.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405730200 · Cited by 78
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Research works printed but not linked: 1
- [5]5. Wolfman A, Macara IG. A cytosolic protein catalyzes the release of GDP from p21ras. Science. 1990;248:67-9 [DOI] [PubMed] [Google Scholar]
Cited by
Items 701–764 of 764
Lubeck, B. A. (2015) · Deep Blue (University of Michigan) · Cited by 1
The Role of Redox-dependent Reactions with Kras Cysteine 118 in Tumorigenesis
Huang, L. (2015) · DukeSpace (Duke University)
Shin, W., Kutmon, M., Mina, E., van Amelsvoort, T., Evelo, C. T., & Ehrhart, F. (2023) · Figshare · doi:10.6084/m9.figshare.24425648
Shin, W., Kutmon, M., Mina, E., van Amelsvoort, T., Evelo, C. T., & Ehrhart, F. (2024) · Figshare · doi:10.6084/m9.figshare.24425829
Geißert, R., Lammert, A., Wirth, S., Hönig, R., Lohfink, D., Unger, M., Pek, D., Schlüter, K., Scheftschik, T., Smit, D. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26674703
Geißert, R., Lammert, A., Wirth, S., Hönig, R., Lohfink, D., Unger, M., Pek, D., Schlüter, K., Scheftschik, T., Smit, D. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26674706
Geißert, R., Lammert, A., Wirth, S., Hönig, R., Lohfink, D., Unger, M., Pek, D., Schlüter, K., Scheftschik, T., Smit, D. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26674700
Additional file 1 of An integrated genetic analysis of epileptogenic brain malformed lesions
Fujita, A., Kato, M., Sugano, H., Iimura, Y., Suzuki, H., Tohyama, J., Fukuda, M., Ito, Y., Baba, S., Okanishi, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26572534
Makino, Y., Arakawa, Y., Yoshioka, E., Shofuda, T., Minamiguchi, S., Kawauchi, T., Tanji, M., Kanematsu, D., Nonaka, M., Okita, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16625380
Geißert, R., Lammert, A., Wirth, S., Hönig, R., Lohfink, D., Unger, M., Pek, D., Schlüter, K., Scheftschik, T., Smit, D. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26674712
Geißert, R., Lammert, A., Wirth, S., Hönig, R., Lohfink, D., Unger, M., Pek, D., Schlüter, K., Scheftschik, T., Smit, D. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26674715
Geißert, R., Lammert, A., Wirth, S., Hönig, R., Lohfink, D., Unger, M., Pek, D., Schlüter, K., Scheftschik, T., Smit, D. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26674709
Kumari, B., Misra, A., Shrivastava, A., Lokhande, K. B., Singh, A., & Roy, P. K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.27.696663
Mbonye, U. R., Bellomo, A., Elhalem, E., Donadio, L. G., Yang, M., Donner, A., Comin, M. J., & Karn, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.14.699500
朱, 含. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161317
Dual targeting of PDPK1 and BRAF V600E is synthetically lethalPreprint
Khaket, T. P., Ghosh, C., Yang, Z., Boufraqech, M., Hu, J., Alamaw, E. D., Andrésson, Þ., O’Neill, M. J., Zhang, Y.-Q., Shen, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.15.711663
Terzić, M., Ak, G., Kochan-Jamrozy, K., Gucwa, M., Stefanowicz‐Hajduk, J., Turecka, K., Hałasa, R., Cziáky, Z., Jekő, J., Şenkardeş, İ., et al. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.116072
Su, G., Yang, S., Fan, B., Jiang, Z., Geng, Y., & Cao, M. (2026) · Molecular Carcinogenesis · doi:10.1002/mc.70073
“Regarding the RAS mutations in A549 (KRAS G12S) and H1299 (NRAS Q61K) cells, these alterations may influence PTPRG‐AS1 expression and function, as RAS signaling can intersect with PI3K/AKT pathways [9, 75].”
Regulation of the protein synthesis machinery in the striatum
Biever, A. (2016) · theses.fr (ABES) · doi:10.70675/d51e3b2cz4ba2z4930z8686z2d89c7f3949d
Dynamique et fonction des interactions entre récepteurs du glutamate et de la dopamine
Goyet, E. (2017) · theses.fr (ABES) · doi:10.70675/20f6bdf0z6083z430dzb1fdz8735d622374d
Cintas, C. (2017) · theses.fr (ABES) · doi:10.70675/d19569d2z4eaez4a9azae8bz1e155d6b15b3
Caye‐Eude, A. (2018) · theses.fr (ABES) · doi:10.70675/5970456azb8a7z44a5zad25zbcef6aab00b1
Exploring PI3K signalling dynamics in pancreatic cancer
Delgado, C. F. R. (2020) · theses.fr (ABES) · doi:10.70675/6df9a059zc3f1z4997z9de2z34a1d24dfbeb
Caractérisation anatomo-clinique et moléculaire du mélanome primitif muqueux
Beaudoux, O. (2020) · theses.fr (ABES) · doi:10.70675/d9fc8370z2051z4b6fzba8dzadf9983952bf
Contrôle de l'oncogenicité de Kras et isoforme beta de PI3K dans la cancérogenèse du pancréas
Arcucci, S. (2019) · theses.fr (ABES) · doi:10.70675/bd0f6cf8zac49z4e36zbe80z39b5e2b4e43a
A yeast-based assay to screen protein-protein interaction modulators
Sudevan, A. (2021) · theses.fr (ABES) · doi:10.70675/9ab04dcaz498fz43ebz8762z012f3f86154c
MAPK pathway modulation and its implications in KRAS mutant lung adenocarcinoma
Román, S. D. H. (2023) · theses.fr (ABES) · doi:10.70675/8eaccae1ze96bz4279zb69fzaafa5e50c341
Radiothérapie interne du mélanome métastatique pigmenté : mécanismes et associations
Rouanet, J. (2019) · theses.fr (ABES) · doi:10.70675/c28349fdz1635z480bzb4e7za5f431ee26c8
LNA GapmeR silencing of KRAS G12V impairs growth and function in SW480 cells
Khudeir, J. F., & Tlili, A. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05545-7
Tang, M., Sallavanti, J., Lanza, M., Covington, D., & Li, W. (2026) · PLoS ONE · doi:10.1371/journal.pone.0348285
Mead, E. H., Batz, K. C., Shih, K.-H., Fleming, I. R., Tesdahl, C. D., Lizardos, L., Armendariz, J. R., Hannan, J. P., Hickey, A. M., Leyk, A., et al. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00815
Choi, P. H., Meredith, J., Sharma, M., Chen, X., Qiu, J., Markov, V., de Stanchina, E., Singh, M., & Rosen, N. X. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117559 · Cited by 2
Ras signalling in infectious disease pathology: Mechanisms, tissue damage, and clinical implications
Husein, A., Jamal, A., Ali, R., Kamal, M. A., Alqurashi, Y. E., Nasim, A., Hussain, S. A., & Hattiwale, H. M. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156609
Acinar-ductal metaplasia in pancreatitis and pancreatic ductal adenocarcinoma
Zhang, X., Zhao, Y., Qin, C., Li, Z., Xie, Y., Yan, Y., Li, T., Huang, L., Shi, H., & Wang, W. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01251-0 · Cited by 3
“…can stimulate mammalian target of rapamycin (mTOR), increasing P70 S6 kinase activity and promoting cell survival, metabolism, and protein synthesis, contributing to ADM [ 48]. mTOR1/2 remodel the actin cytoskeleton via Arp2/3 complex, caus - ing the transformation of acinar cell morphology [49].”
Li, H., Jiang, Q., Guan, J., He, X., Xie, P., Zhao, Z., Liu, X., Liu, X., Lee, T.-Y., Wei, L., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119134
Reconstitution of Ras-PI3Kγ membrane communication and feedback using light-induced signaling inputs
Doerr, S., Colasurdo, A. O., & Hansen, S. D. (2026) · Nature Communications · doi:10.1038/s41467-026-75652-y · Cited by 1
“Since the Ras-PI3K γ signaling module is broadly important for immune cell function, it is unsur-prising that dysregulation of this pathway plays a role in numerous in fl ammatorydiseasesandcancers 11,16,17 .”
Crosstalk between the Wnt pathway and other signaling pathways
Flores-Hernández, E., Binder, G., Chen, H., & Tejeda‐Muñoz, N. (2026) · Cells and Development · doi:10.1016/j.cdev.2026.204099
Dual control of PIP2 drives germline/soma segregation in Drosophila
Kilwein, M. D., Yang, L., Marmion, R. A., Wynter, C., Nakamura, A., Shvartsman, S. Y., & Gavis, E. R. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2604429123
Targeting EGFR Endocytosis and Signaling for Cancer Drug Delivery and Cancer Treatment
Chen, X., & Wang, Z. (2026) · Cancers · doi:10.3390/cancers18152451 · Cited by 3
“Activated EGFR triggers PI3K either directly via p85 α or indirectly through Ras [39,40].”
Protein–Protein Interactions: Emerging Drug Targets
Silverman, R. B., Xue, F., & Juncosa, J. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15862-9.00010-2
4H‐CRCXL Mitigates RasV12‐Induced Phenotypes in Glioblastoma Model of Drosophila
Kumar, P., Raghuvanshi, V., Kumar, P., Kumar, R., Chauhan, B. S., Katiyar, D., & Srikrishna, S. (2026) · Molecular Carcinogenesis · doi:10.1002/mc.70161
Karim, M. U., Martínez, C., Khan, A. M. H., Baksh, A. R., Joseph, A., Panet-Raymond, V., TSIEN, C., Kopek, N., & Abdulkarim, B. (2026) · Advances in Radiation Oncology · doi:10.1016/j.adro.2026.102176
Jo, K., Kim, A. J., Kim, S. Y., Kim, D.-S., Kim, C., 손은중, & Lee, Y. M. (2026) · Pharmaceuticals · doi:10.3390/ph19091422
Nuha, N., Higgins, C. E., Higgins, S. P., Samarakoon, R., & Higgins, P. J. (2026) · Biomolecules · doi:10.3390/biom16101517
“Mutant KRAS constitutively activates downstream PI3K/AKT and MAPK pathways driving cellular proliferation, increased motility and tumor cell survival while promoting development of a dense, highly fibrotic (desmoplastic) stromal microenvironment [6,7].”
Wang, X., Ding, L., Meng, W., Byrnes, E., Loo, S. K., Sun, S., Chen, L., Li, T., Wang, M.-T., Pennathur, A., et al. (2026) · Science Advances · doi:10.1126/sciadv.aeb9836
“For example, ERK interacts with multiple nodes of the PI3K/AKT/mTOR pathway, including its phosphorylation of TSC2 ( 52 , 53 ).”
Naseem, T., Khan, H., & Parvez, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27544-9.00018-0
BindingDB (2020) · UC San Diego · doi:10.7270/q29w0j00
BindingDB (2026) · UC San Diego · doi:10.7270/q2t4401d
BindingDB (2013) · UC San Diego · doi:10.7270/q26w9ccb
Li, M., Xiao, T., Chen, X., Liu, Z., Ji, H., Chen, H., Xi, X., Zhang, Y., & Zhu, X. (2026) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2026.102455
Role of phosophoinositide-based signaling in virulence in Entamoeba histolytica
Koushik, A. B. (2013) · TigerPrints (Clemson University)
Metadata
- Authors
- Castellano, E., & Downward, J.
- Affiliations
- Cancer Research UK (GB)
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 261-274
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- PMC
- PMC3128635
- OpenAlex
- W2047401805
- Cited by
- 762
- References
- 206
- Citations by year
- 2026: 32 · 2025: 38 · 2024: 50 · 2023: 52 · 2022: 48 · 2021: 82 · 2020: 69 · 2019: 59 · 2018: 50 · 2017: 43 · 2016: 55 · 2015: 54 · 2014: 42 · 2013: 45 · 2012: 37
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Genes & Cancer (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- Ras, phosphatidylinositol 3-kinase, oncogenic KRAS, HRAS, p110α, PI3K inhibitors, Raf/MEK/ERK pathway, combination cancer therapy, tumor resistance, lung carcinogenesis, skin carcinogenesis, small GTPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.